As the Trump administration erodes U.S. | As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.
START SELLING WITH BigBCC TODAY
Start your free trial with BigBCC today.
BLOG | Business
Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials





